The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: A randomized trial by the Gruppo Italiano Studio Linfomi (GISL)

P. G. Gobbi, C. Broglia, F. Valentino, C. Mammi, M. Lombardo, F. Merli, S. Luminari, G. Polimeno, A. Riezzo, P. Lambelet, A. Rovati, G. R. Corazza, M. Federico

Research output: Contribution to journalArticlepeer-review

Abstract

Background: It is still unclear the actual contribute of dose intensity (DI), dose size (DS) and dose density (DD) in the conventional chemotherapy of large, B-cell non-Hodgkin lymphomas. Methods: A prospective, randomized trial compared the cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles) with a modified version of it, which administered the same drugs sequentially (seq-PC), with the same planned cumulative DI and an 83% DD, within the same time frame (113 days), but with three times higher DS of all the drugs except vincristine. Results: Fifty-six patients received cyc-PC and 52 seq-PC. The actual mean cumulative DI was 0.79 ± 0.15 with cyc-PC, 0.78 ± 0.17 with seq-PC. Response was complete in 59% and 52%, partial in 20% and 21%, null in 5% and 6%, respectively. There were four toxic deaths (two per arm). Relapses occurred in 36% and 37%, respectively. Toxicity was similar in both arms. Overall, failure-free, progression-free and disease-free survival (median follow-up: 54 months) were statistically indifferent. Conclusions: The very similar DI actually delivered in both arm seems to be the main common determinant of the indifferent results recorded. Increasing DS - at least within the limits clinically attainable without stem cell rescue - does not improve results.

Original languageEnglish
Pages (from-to)676-682
Number of pages7
JournalAnnals of Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2006

Keywords

  • Chemotherapy
  • Dose density
  • Dose intensity
  • Dose size
  • Large B-cell lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: A randomized trial by the Gruppo Italiano Studio Linfomi (GISL)'. Together they form a unique fingerprint.

Cite this